A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Researchers from The University of Osaka identify a molecule that can support specific therapeutic targeting of AML with ...

“It’s important in leukemia, lymphoma or other blood cancers that we actually target and eliminate these stem cells, because ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

Scientists have identified a promising new drug target for acute myeloid leukemia, a deadly blood cancer with a five-year ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

Novel CAR T cells and cord blood-derived CAR NK cells for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. When a patient with KG2032-reactive AML ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

RAPID-CRISPR test quickly and accurately diagnoses acute promyelocytic leukemia, a rare and aggressive blood cancer, with ...